Heart disease continues to top the list as the leading cause of death in the US, claiming around 700,000 lives annually. Now, new research suggests that nearly 50,000 of those deaths could be prevented each year with a simple but powerful treatment approach: combining cholesterol-lowering medications. "The combination therapy is safe and efficacious," said Maciej Banach, the study's first author and professor of cardiology at the John Paul II Catholic University of Lublin, Poland.High cholesterol plays a central role in the development of heart disease by causing plaque buildup in arteries, which restricts blood flow and can lead to heart attacks or strokes. Statins, which reduce the liver’s production of cholesterol, are already commonly prescribed for patients at high risk. But Banach and his team found that pairing statins with ezetimibe—a drug that blocks the small intestine from absorbing cholesterol—can significantly improve outcomes.Nearly 20% Reduction In DeathsAccording to the findings, patients on the combination therapy saw a 19% reduction in the risk of early death, an 18% lower chance of experiencing a major cardiovascular event, and a 17% decrease in the risk of stroke. The findings were published in the journal Mayo Clinic Proceedings.Ezetimibe, sold under the brand name Zetia, works differently from statins by targeting cholesterol absorption in the gut rather than production in the liver. The research challenges the traditional view that patients should be monitored on high-dose statins for at least two months before introducing ezetimibe.Banach’s team based their recommendation on a review of 14 studies involving over 108,000 patients with blocked arteries. Their conclusion is clear: the combination approach shouldn’t be delayed.“This study confirms that combined cholesterol-lowering therapy should be considered immediately and should be the gold standard for treatment of very high-risk patients,” said study co-author Peter Toth. “Simply adding ezetimibe to statin therapy, without waiting for at least two months to see the effects of statin monotherapy, which is suboptimal in many patients, is associated with more effective LDL goal achievement and is responsible for significant incremental reductions in cardiovascular health problems and deaths.”The approach is also cost-effective. “It does not require additional funding or reimbursement of new expensive drugs,” Toth added. “In fact, it may translate into lower rates of first and subsequent heart attacks and stroke, and their complications like heart failure, which are extremely costly for all health care systems.”Cardiovascular disease is responsible for nearly 20 million deaths globally each year, driven by high blood pressure, smoking, obesity, physical inactivity, diabetes, and high cholesterol. In the US alone, an estimated 94 million adults have borderline high cholesterol.Dr. Benjamin Hirsh, director of preventive cardiology at North Shore University Hospital, said he hopes early combination therapy becomes the new standard. “For very high-risk patients, there is no reason to wait,” he said. "Aggressive reduction of LDL cholesterol is paramount."